# Rigel Pharmaceuticals

Type: Company (RIGL)

Source: GetYourBrief — https://getyourbrief.com/entity/rigel-pharmaceuticals
Canonical HTML page: https://getyourbrief.com/entity/rigel-pharmaceuticals

## Timeline

- **2026-03-03**: Q4 Earnings Release — Both companies scheduled to report full-year 2025 financial results.
- **2025-09-15**: ARCT-032 Phase 1b — Arcturus releases positive interim data for Cystic Fibrosis candidate.
- **2023-11-28**: Kostaive Approval — Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.

## Recent coverage (6 stories, network-wide)

### Specialty Pharma Resilience: Cumberland and Rigel Navigate Q4 Headwinds
2026-03-05 12:12:41 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Cumberland and Rigel Pharmaceuticals reported Q4 2025 results, highlighting strategic shifts toward high-margin specialty products and oncology expansions. While Cumberland focuses on hospital-channel optimization, Rigel is doubling down on its hematology-oncology portfolio to drive long-term growth.
Full story: https://getfinancebrief.com/story/cumberland-rigel-q4-earnings-analysis

### Rigel and Cumberland Q4 Results Signal Commercial Maturity in Specialty Pharma
2026-03-05 12:08:35 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Rigel Pharmaceuticals and Cumberland Pharmaceuticals reported Q4 results that emphasize commercial execution and a shift toward sustainable profitability. Both companies are leveraging core hospital and oncology assets to navigate a market that increasingly rewards revenue-generating biotechs over speculative R&D.
Full story: https://getbiobrief.com/story/rigel-cumberland-q4-earnings-analysis-2026

### Specialty Pharma Resilience: Rigel and Cumberland Q4 Earnings Analysis
2026-03-05 12:08:31 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Rigel and Cumberland Pharmaceuticals reported Q4 results highlighting steady commercial growth in specialty oncology and hospital-based therapies. Both companies are prioritizing portfolio optimization and pipeline advancement to navigate a competitive biotech landscape.
Full story: https://gethealthbrief.com/story/rigel-cumberland-q4-earnings-specialty-pharma-analysis

### Biotech Execution in Focus: Arcturus and Rigel Set for Q4 Earnings Results
2026-03-02 22:55:18 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Full story: https://getfinancebrief.com/story/arcturus-rigel-q4-2025-earnings-preview

### Arcturus and Rigel Q4 Previews: mRNA Innovation vs. Oncology Commercialization
2026-03-02 22:54:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Full story: https://getbiobrief.com/story/arcturus-rigel-q4-2025-earnings-preview

### Biotech Earnings Preview: Arcturus and Rigel Set for Pivotal Q4 Reports
2026-03-02 22:53:40 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Full story: https://gethealthbrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.